Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 11,366 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 11,366 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.29, for a total value of $173,786.14. Following the completion of the sale, the insider now directly owns 106,669 shares in the company, valued at $1,630,969.01. This trade represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Malcom Rodman also recently made the following trade(s):

• On Monday, April 14th, David Malcom Rodman sold 11,366 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.53, for a total value of $165,147.98.
• On Tuesday, April 1st, David Malcom Rodman sold 55,771 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $15.76, for a total value of $878,950.96.

Mineralys Therapeutics Stock Performance

Shares of NASDAQ:MLYS opened at $15.35 on Friday. The company’s 50-day moving average is $14.29 and its 200 day moving average is $12.47. The company has a market capitalization of $1.00 billion, a P/E ratio of -4.22 and a beta of -0.30. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.23. As a group, research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Institutional Trading of Mineralys Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its holdings in Mineralys Therapeutics by 55.4% during the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company’s stock worth $13,319,000 after purchasing an additional 385,726 shares in the last quarter. Barclays PLC raised its holdings in shares of Mineralys Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 38,218 shares of the company’s stock valued at $463,000 after acquiring an additional 28,208 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Mineralys Therapeutics by 43.0% in the 4th quarter. Wellington Management Group LLP now owns 91,529 shares of the company’s stock valued at $1,127,000 after acquiring an additional 27,531 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Mineralys Therapeutics in the 4th quarter valued at about $285,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Mineralys Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company’s stock valued at $2,645,000 after acquiring an additional 1,307 shares in the last quarter. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. The Goldman Sachs Group cut their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. HC Wainwright reissued a “buy” rating and issued a $42.00 price target on shares of Mineralys Therapeutics in a research note on Tuesday, May 13th. Finally, Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.